Related references
Note: Only part of the references are listed.Serum ACE2, Angiotensin II, and Aldosterone Levels Are Unchanged in Patients With COVID-19
Marina Rieder et al.
AMERICAN JOURNAL OF HYPERTENSION (2021)
COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection
Stephany Beyerstedt et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2021)
Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients
Tamara S. Rodrigues et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2021)
Potential detrimental role of soluble ACE2 in severe COVID-19 comorbid patients
Mohammad Mahmudur Rahman et al.
REVIEWS IN MEDICAL VIROLOGY (2021)
The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients
Xiaokang He et al.
SCIENTIFIC REPORTS (2021)
A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient
Bela Nagy et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Latent class cluster analysis identified hidden headache phenotypes in COVID-19: impact of pulmonary infiltration and IL-6
Omer Karadas et al.
NEUROLOGICAL SCIENCES (2021)
Renin-angiotensin-aldosterone system peptide profiles in patients with COVID-19
Alexander Kutz et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2021)
Pretreatment with High Mobility Group Box-1 Monoclonal Antibody Prevents the Onset of Trigeminal Neuropathy in Mice with a Distal Infraorbital Nerve Chronic Constriction Injury
Takahiro Kochi et al.
MOLECULES (2021)
Molecular Characteristics of RAGE and Advances in Small-Molecule Inhibitors
Hyeon Jin Kim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Migraine and neuroinflammation: the inflammasome perspective
Oguzhan Kursun et al.
JOURNAL OF HEADACHE AND PAIN (2021)
Plasma ACE2 predicts outcome of COVID-19 in hospitalized patients
Tue W. Kragstrup et al.
PLOS ONE (2021)
Circulating Levels of Calcitonin Gene-Related Peptide Are Lower in COVID-19 Patients
Laura Ochoa-Callejero et al.
JOURNAL OF THE ENDOCRINE SOCIETY (2021)
Urgent Need for ICHD Criteria for COVID-19-Related Headache: Scrutinized Classification Opens the Way for Research
Betul Baykan et al.
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY (2021)
Neural-respiratory inflammasome axis in traumatic brain injury
Nadine Kerr et al.
EXPERIMENTAL NEUROLOGY (2020)
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target
Haibo Zhang et al.
INTENSIVE CARE MEDICINE (2020)
Neuraxial Cytokines in Pain States
Gilson Goncalves dos Santos et al.
FRONTIERS IN IMMUNOLOGY (2020)
Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19
Adnan Shah
FRONTIERS IN IMMUNOLOGY (2020)
COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children
Elena Ciaglia et al.
FRONTIERS IN PEDIATRICS (2020)
Re The source of elevated plasma D-dimer levels in COVID-19 infection
Beverley J. Hunt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Spectrum of Headaches Associated With SARS-CoV-2 Infection: Study of Healthcare Professionals
Jesus Porta-Etessam et al.
HEADACHE (2020)
Case Series of Headache Characteristics in COVID-19: Headache Can Be an Isolated Symptom
Tugce Toptan et al.
HEADACHE (2020)
Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients
Liting Chen et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
Factors associated with the presence of headache in hospitalized COVID-19 patients and impact on prognosis: a retrospective cohort study
Javier Trigo et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Headache characteristics in COVID-19 pandemic-a survey study
Ozge Uygun et al.
JOURNAL OF HEADACHE AND PAIN (2020)
Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression
Mary Kathryn Bohn et al.
PHYSIOLOGY (2020)
The Inflammasome in Times of COVID-19
Juan Carlos de Rivero Vaccari et al.
FRONTIERS IN IMMUNOLOGY (2020)
HMGB1 as a potential biomarker and therapeutic target for severe COVID-19
Ruochan Chen et al.
HELIYON (2020)
Are Migraine Patients at Increased Risk for Symptomatic Coronavirus Disease 2019 Due to Shared Comorbidities?
Hayrunnisa Bolay et al.
HEADACHE (2020)
Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients
Zhiyong Wu et al.
CRITICAL CARE (2020)
Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors
Huan Han et al.
EMERGING MICROBES & INFECTIONS (2020)
Non-invasive dural stimulation in mice: A novel preclinical model of migraine
Carolina Christina Burgos-Vega et al.
CEPHALALGIA (2019)
Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model
Wei He et al.
JOURNAL OF NEUROINFLAMMATION (2019)
Migraine and the trigeminovascular system-40 years and counting
Messoud Ashina et al.
LANCET NEUROLOGY (2019)
JASP: Graphical Statistical Software for Common Statistical Designs
Jonathon Love et al.
JOURNAL OF STATISTICAL SOFTWARE (2019)
Sensory neuronal sensitisation occurs through HMGB-1-RAGE and TRPV1 in high-glucose conditions
Samuel M. Bestall et al.
JOURNAL OF CELL SCIENCE (2018)
HMGB1 Increases IL-1β Production in Vascular Smooth Muscle Cells via NLRP3 Inflammasome
Eun Jung Kim et al.
FRONTIERS IN PHYSIOLOGY (2018)
Interleukin-6: an emerging regulator of pathological pain
Ya-Qun Zhou et al.
JOURNAL OF NEUROINFLAMMATION (2016)
HMGB1 promotes the activation of NLRP3 and caspase-8 inflammasomes via NF-κB pathway in acute glaucoma
Wei Chi et al.
JOURNAL OF NEUROINFLAMMATION (2015)
Severe acute respiratory syndrome coronavirus E protein transports calcium ions and activates the NLRP3 inflammasome
Jose L. Nieto-Torres et al.
VIROLOGY (2015)
Identification of a functional interaction of HMGB1 with Receptor for Advanced Glycation End-products in a model of neuropathic pain
Yohance M. Allette et al.
BRAIN BEHAVIOR AND IMMUNITY (2014)
EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial
Andrew S. C. Rice et al.
LANCET (2014)
Retinal Ischemia/Reperfusion Injury Is Mediated by Toll-like Receptor 4 Activation of NLRP3 Inflammasomes
Yun Qi et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2014)
Extracellular High-Mobility Group Box 1 Protein (HMGB1) as a Mediator of Persistent Pain
Nilesh M. Agalave et al.
MOLECULAR MEDICINE (2014)
Angiotensin II produces nociceptive behavior through spinal AT1 receptor-mediated p38 mitogen-activated protein kinase activation in mice
Wataru Nemoto et al.
MOLECULAR PAIN (2013)
The persistent release of HMGB1 contributes to tactile hyperalgesia in a rodent model of neuropathic pain
Polina Feldman et al.
JOURNAL OF NEUROINFLAMMATION (2012)
Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6)
Jin Yan et al.
MOLECULAR PAIN (2012)
Enhanced excitability of nociceptive trigeminal ganglion neurons by satellite glial cytokine following peripheral inflammation
Mamoru Takeda et al.
PAIN (2007)
Nuclear factor-κB as a molecular target for migraine therapy
U Reuter et al.
ANNALS OF NEUROLOGY (2002)
Delayed inflammation in rat meninges: implications for migraine pathophysiology
U Reuter et al.
BRAIN (2001)
Involvement of the proinflammatory cytokines tumor necrosis factor-α, IL-1β,and IL-6 but not IL-8 in the development of heat hyperalgesia:: Effects on heat-evoked calcitonin gene-related peptide release from rat skin
A Oprée et al.
JOURNAL OF NEUROSCIENCE (2000)
Share Paper
